Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028187 | 0.81 | MEN1 (0.47) | MEN1KMT2ATSHRTP53PABPC1 | |
| SCHEMBL4025880 | 0.78 | MEN1 (0.47) | MEN1KMT2ATSHRTP53PABPC1 | |
| SCHEMBL4022505 | 0.78 | MEN1 (0.44) | MEN1KMT2ATSHRTP53PABPC1 | |
| SCHEMBL13870055 | 0.77 | MEN1 (0.41) | MEN1KMT2ATP53PABPC1SMN1; SMN2 | |
| SCHEMBL8926305 | 0.75 | HSD17B10 (0.61) | MEN1KMT2ATSHRADORA2BMAPK1 | |
| SCHEMBL9371648 | 0.72 | MEN1 (0.57) | MEN1KMT2ATSHRTP53ADORA2B | |
| SCHEMBL15484962 | 0.72 | LMNA (0.51) | MEN1KMT2ATSHRTP53PABPC1 | |
| SCHEMBL9426305 | 0.72 | MEN1 (0.54) | MEN1KMT2ATSHRADORA2BMAPK1 | |
| SCHEMBL17963635 | 0.71 | TSHR (0.47) | MEN1KMT2ATSHRTP53ADORA2B | |
| SCHEMBL10582443 | 0.71 | TSHR (0.53) | MEN1KMT2ATSHRADORA2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524823-B2 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| EP-1846430-B1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| EP-1846430-A1 | NEW MACROLIDES | Basilea Pharmaceutica AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060264387-A1 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2006-11-23 | — | — | US | disclosed |
| WO-2006084410-A1 | NEW MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264387-A1 | Macrolides | PPME1, MGAM, SMPD1 | MEN1 1597/4885KMT2A 4641/4885TSHR 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.